[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523248":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":64,"collaborators":10,"id":67,"slug":10,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Oulu","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Before salbutamol",null,"Participants before the administration of salbutamol",{"label":13,"type":10,"description":14,"interventionNames":15},"After salbutamol","Participants after the administration of salbutamol",[16],"Drug: Salbutamol",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Salbutamol","Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.",[13],[24],{"name":25,"affiliation":5,"role":26},"Terhi Tapiainen, Professor","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Ville Lindholm, MD","CONTACT","+35883155283","Ville.a.lindholm@oulu.fi",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Department of Pediatrics, Oulu University Hospital","RECRUITING","Oulu","90130","Finland",{"type":41,"coordinates":42},"Point",[43,44],25.46816,65.01236,{"lat":44,"lon":43},[47,49,53,54,56,58,60,62],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":48},"Ville.a.lindholm@student.oulu.fi",{"name":50,"role":30,"phone":51,"phoneExt":10,"email":52},"Terhi Tapiainen, MD, PhD","+358-8-315 5185","terhi.tapiainen@oulu.fi",{"name":50,"role":26,"phone":10,"phoneExt":10,"email":10},{"name":29,"role":55,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":57,"role":55,"phone":10,"phoneExt":10,"email":10},"Minna Honkila, MD, PhD",{"name":59,"role":55,"phone":10,"phoneExt":10,"email":10},"Tytti Pokka, MSc",{"name":61,"role":55,"phone":10,"phoneExt":10,"email":10},"Niko Paalanne, MD, PhD",{"name":63,"role":55,"phone":10,"phoneExt":10,"email":10},"Tuomas Jartti, MD, PhD",{"type":26,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Terhi Tapiainen","Professor of Pediatrics, Head of Pediatric Infectious Diseases and Emergency Department","100523248",false,"NCT06093152","Video Assisted Study of Salbutamol Response in Viral Wheezing","ViVi","Inclusion Criteria:\n\n* Wheezing\n* Salbutamol-treatment in emergency department prescribed\n\nExclusion Criteria:\n\n* Need for immediate resuscitation\n* Immediate transfer to ICU\n* Suspicion of pneumonia based on the auscultation finding\n* Suspicion of airway foreign body","ALL","6 Months","24 Months",{"count":77,"type":78},50,"ESTIMATED","OBSERVATIONAL","The study is video assisted cross-over study evaluating the effect of inhaled salbutamol in wheeze in children 6-24 months old.",[82],"Wheezing","2025-02-11",{"date":85,"type":86},"2025-02-13","ACTUAL",{"date":88,"type":86},"2023-10-23",{"date":90,"type":78},"2026-12",{"name":5,"class":6},1]